TNNI3K Inhibitors
TNNI3K inhibitor is a class of chemical compounds that has gained significant attention in the field of molecular biology and pharmacology due to its potential role in modulating specific cellular processes. These inhibitors are designed to target the TNNI3K enzyme, which is a serine/threonine kinase found in various tissues, particularly in the cardiac muscle. The primary function of TNNI3K, also known as cardiac-specific kinase TNNI3K (cTnI-interacting kinase), is to phosphorylate troponin I (cTnI), a crucial protein involved in the regulation of muscle contraction in the heart. By inhibiting the activity of TNNI3K, these chemical compounds have the potential to influence various cellular signaling pathways and physiological responses, although their precise mechanisms of action are still being studied.
TNNI3K inhibitors typically function by binding to the active site of the enzyme, it from phosphorylating its substrate, cTnI. This inhibition can lead to alterations in the intracellular calcium levels, as cTnI phosphorylation is closely associated with calcium handling in cardiac muscle cells. Consequently, TNNI3K inhibitors have the potential to impact cardiac contractility and electrical signaling, making them a subject of interest in cardiac research. Furthermore, these inhibitors may also have broader implications beyond the cardiac system, as TNNI3K is found in other tissues, including skeletal muscle and certain neural tissues.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases, including TNNI3K, by competing with ATP for binding to the catalytic site of the kinase. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $153.00 $464.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor that can also inhibit other kinases like TNNI3K by binding to the ATP-binding site, thereby blocking its catalytic activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that can inhibit TNNI3K activity by competing with ATP for binding to the kinase domain. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that can inhibit TNNI3K by binding to its ATP-binding site, leading to inhibition of its kinase activity. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib is a MEK inhibitor that can indirectly inhibit TNNI3K activity by disrupting downstream signaling pathways that TNNI3K is involved in. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of CDK4/6 which can indirectly affect TNNI3K activity by influencing the cell cycle and proliferation pathways that TNNI3K may regulate. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762 is a checkpoint kinase inhibitor that may indirectly influence TNNI3K activity by affecting DNA damage response pathways where TNNI3K might play a role. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2 that can indirectly inhibit TNNI3K by interfering with receptor tyrosine kinase signaling that TNNI3K might be associated with. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that can indirectly inhibit TNNI3K by targeting various signaling pathways, including RAF/MEK/ERK, which TNNI3K may impact. | ||||||